SCHEMBL5583124

SCHEMBL5583124

O=C(c1ccc2[nH]c3c(c2c1)CCCc1cn[nH]c1-3)N1CCC(O)(c2cccc(F)c2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 9/20 0.48
RIPK1 Q13546 7/20 0.48
CYP2C9 P11712 3/20 0.47
CYP2C19 P33261 3/20 0.47
CYP3A4 P08684 2/20 0.47
KDR P35968 1/20 0.46
PKLR P30613 1/20 0.42
ALDH1A1 P00352 4/20 0.42
LMNA P02545 4/20 0.42
MAPT P10636 4/20 0.42
MAPK1 P28482 3/20 0.42
KDM4E B2RXH2 3/20 0.42
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
HSD17B10 Q99714 3/20 0.42
USP2 O75604 1/20 0.42
HSP90AA1 P07900 1/20 0.42
ALOX15 P16050 1/20 0.42
GFER P55789 1/20 0.42
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5583182 0.91 MAPK10 (0.51) MAPK10RIPK1CYP2C9CYP2C19CYP3A4
SCHEMBL5583232 0.91 MAPK10 (0.53) MAPK10RIPK1KDRALDH1A1LMNA
SCHEMBL5583281 0.90 MAPK10 (0.48) MAPK10RIPK1CYP2C9CYP2C19CYP3A4
SCHEMBL5582988 0.90 ACACB (0.45) MAPK10RIPK1CYP3A4KDRPKLR
SCHEMBL5582981 0.89 MAPK10 (0.45) MAPK10RIPK1CYP2C9CYP2C19CYP3A4
SCHEMBL5583121 0.88 MAPK10 (0.51) MAPK10RIPK1CYP3A4KDRPKLR
SCHEMBL5583154 0.88 MAPK10 (0.51) MAPK10RIPK1KDRPKLRALDH1A1
SCHEMBL5583118 0.88 MAPK10 (0.49) MAPK10RIPK1KDRPKLRALDH1A1
SCHEMBL5583289 0.88 MAPK10 (0.46) MAPK10RIPK1CYP2C9CYP2C19CYP3A4
Sulfuric Acid SCHEMBL5583133 0.87 PKLR (0.46) MAPK10RIPK1CYP2C19CYP3A4KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US claimed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer TAKADA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-11-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070254877-A1 Indole Derivative and Use for Treatment of Cancer IGF1R, KDR, ERBB2 MAPK10 1222/4885RIPK1 702/4885CYP2C9 707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.